Last reviewed · How we verify
Superficial basal cell carcinoma
Approved treatments
- Carac · Spectrum Pharms
- Carac · Extrovis
- Aldara · Bausch Health
Aldara works by activating the immune system to recognize and attack abnormal cells.
Clinical guidelines
- FDA label — 1L
In the 5% strength, it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Superficial basal cell carcinoma patent landscape — cliff calendar, originator estates, attackable patents
- Superficial basal cell carcinoma treatment landscape brief
- Superficial basal cell carcinoma treatment updates RSS
Frequently asked questions about Superficial basal cell carcinoma
What drugs treat Superficial basal cell carcinoma?
Tracked treatments include Carac, Aldara.
What is the treatment for Superficial basal cell carcinoma?
Standard treatment for Superficial basal cell carcinoma includes Carac, Aldara. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Superficial basal cell carcinoma?
FDA label publishes guidelines for Superficial basal cell carcinoma. 1 guideline references tracked.
Related
- Treatment landscape: Superficial basal cell carcinoma patent cliff · Superficial basal cell carcinoma CI report
- Treatment: Carac · Spectrum Pharms
- Treatment: Carac · Extrovis
- Treatment: Aldara · Bausch Health
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing